Literature DB >> 12151184

The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays.

M J Alfa1, B Swan, B VanDekerkhove, P Pang, G K M Harding.   

Abstract

This study prospectively compared; Triage(R) C. difficile test (TCT), TechLab C. difficile toxin A-B enzyme immuno-assay (EIA), and cell-culture cytotoxin test (CT). Of the 400 stools tested, 99 were positive by any test with 92, 41 and 58 detected by TCT, EIA and CT, respectively. Culture of discordant samples indicated that 52 contained C. difficile (42 toxigenic, 10 non-toxigenic), 10 contained Clostridium species and 2 had no detectable clostridium isolates. There were 21/42 toxigenic C. difficile isolates from 17 patients whose stools were negative when originally tested by CT. Review of available patient charts indicated that 12/14 did not previously or currently have C. difficile associated diarrhea, whereas 2 patients developed disease within a few days. Compared to CT as the gold standard, the sensitivity and specificity were; 93%, 89% and 66%, 99% for TCT and EIA respectively. The 8 stool samples with Toxin A(-) Toxin B(+) isolates were detected in 8, 4, and 6 samples by TCT, EIA and CT, respectively. In summary, TCT as a screening test allowed reliable reporting for 85% of stools on the day of receipt. For the 15% of stools requiring further testing we recommend the use of CT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151184     DOI: 10.1016/s0732-8893(02)00413-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  14 in total

1.  Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin.

Authors:  John R Ticehurst; Deborah Z Aird; Lisa M Dam; Anita P Borek; John T Hargrove; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay.

Authors:  Daniel M Musher; Atisha Manhas; Pranav Jain; Franziska Nuila; Amna Waqar; Nancy Logan; Bernard Marino; Edward A Graviss
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

3.  Combination of culture, antigen and toxin detection, and cytotoxin neutralization assay for optimal Clostridium difficile diagnostic testing.

Authors:  Michelle J Alfa; Shadi Sepehri
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

4.  Evaluation of a Gastrointestinal Pathogen Panel Immunoassay in Stool Testing of Patients with Suspected Clostridioides (Clostridium) difficile Infection.

Authors:  Marcela Krutova; Ales Briksi; Jan Tkadlec; Miroslav Zajac; Jana Matejkova; Otakar Nyc; Pavel Drevinek
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

5.  Rapid detection of Clostridium difficile in feces by real-time PCR.

Authors:  Simon D Bélanger; Maurice Boissinot; Natalie Clairoux; François J Picard; Michel G Bergeron
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

6.  Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study.

Authors:  Seth R Shaffer; Zoann Nugent; Andrew Walkty; B Nancy Yu; Lisa M Lix; Laura E Targownik; Charles N Bernstein; Harminder Singh
Journal:  CMAJ Open       Date:  2020-11-16

7.  Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile.

Authors:  Ann M Larson; Angela M Fung; Ferric C Fang
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

Review 8.  Clostridium difficile-associated diarrhea in adults.

Authors:  Susan M Poutanen; Andrew E Simor
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

9.  Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection.

Authors:  A Walkty; P R S Lagacé-Wiens; K Manickam; H Adam; P Pieroni; D Hoban; J A Karlowsky; M Alfa
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

10.  Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A.

Authors:  Ruth Murray; Dave Boyd; Paul N Levett; Michael R Mulvey; Michelle J Alfa
Journal:  BMC Infect Dis       Date:  2009-06-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.